You can buy or sell ALDR and other stocks, options, ETFs, and crypto commission-free!
Alder BioPharmaceuticals, Inc. Common Stock, also called Alder BioPharmaceuticals, is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Read More Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.
52 Week High
52 Week Low
Yahoo FinanceMay 7
Here’s What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)
With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter.
Yahoo FinanceMay 6
Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials
Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate more than 50% of patients achieved rapid onset of migraine prevention with eptinezumab on Day 1 across four clinical trials BOTHELL, Wash., May 06, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new efficacy data highlighting consistency of early migraine prevention benefit across fou...
The Motley FoolMay 3
Alder BioPharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Call Transcript
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Q1 2019 Earnings Call May 2, 2019, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon and welcome to the Alder Biopharmaceuticals first quarter 2019 financial results conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's requ...
Expected Aug 6, After Hours